

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

98 JAN 26 PM 2:57

Applicant(s): Christine L. Brakel et al. GROUP 280
 Serial No.: 07/446,235 Group Art Unit: 1803
 Filed: December 4, 1989 Examiner: Gary L. Kunz
 For: **MODIFIED NUCLEOTIDE COMPOUND**

Honorable Commissioner of
 Patents and Trademark
 Washington, D.C. 20231

Sir:

Transmitted herewith is a response (Amendment Under 37 C.F.R. §1.115) in the above-identified patent application.

The fee* has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total	51	Minus	51	= 0	x 11	\$ 0
Indep	7	Minus	7	= 0	x 37	\$ 0
() First Presentation of Multiple Dependent Claims					+ 115	\$ 0
TOTAL ADDITIONAL FEE -----						\$ 0

* Small entity status is established in this application by a properly signed declaration submitted herewith.

(X) Charge Deposit Account No. 05-1135 in the amount of \$ ____

() A check in the amount of \$ _____ is attached.

(X) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 05-1135: any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims and any patent application processing fees under 37 C.F.R. §1.17.

Copies are being provided in triplicate.

DECEMBER 7, 1992
 Date


ENZO THERAPEUTICS, INC.
 c/o Enzo Biochem, Inc.
 60 Executive Boulevard
 Farmingdale, New York 11735
 Tel. (212) 856-0876

Attorney's Docket No.: **Enz-47**

Respectfully submitted,



Ronald C. Fedus
 Registration No. 32,567
 Attorney for Applicant(s)

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner of Patents & Trademarks Washington, D.C. 20231	
 Ronald C. Fedus Reg. No. 32,567	12/7/92 Date